Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects

NCT04480710 is registered in ClinicalTrials.gov with Hepion Pharmaceuticals, Inc. as lead sponsor.

NCT NCT04480710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04480710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AMBITION: A Phase 2A, Multiple-Center, Single-Blind, Placebo-Controlled Study To Evaluate The Safety and Tolerability of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects
Lead sponsor
Hepion Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 23, 2020
Completion date
October 30, 2021
Enrollment
47 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

fibrosis, liver, nafld - nonalcoholic fatty liver disease, nash - nonalcoholic steatohepatitis